Rucaparib acetate is an orally active inhibitor of PARP proteins (PARP-1, PARP-2, and PARP-3) with a Ki of 1.4 nM for PARP-1; it also acts as an inhibitor of hexose-6-phosphate dehydrogenase (H6PD) and shows potential for the research of castration-resistant prostate cancer (CRPC).